Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma

British Journal of Haematology

Volumn 105, Issue 4, 1999, Pages 938-941

  Fassas, Athanasios B T ^b   Desikan, K R ^a   Siegel, David ^a   Golper, Thomas A ^a   Munshi, Nikhil C ^a   Barlogie, Bart ^a   Tricot, Guido ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

High risk features; Multiple myeloma; Renal function; Tumour lysis syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME;

EID: 0033060286     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01467.x     Document Type: Article

References (19)

1. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91-97.
2. Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. & Crowley, J. (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, 55-65.
3. Barlogie, B., Jagganath, S., Vesole, D.H., Naucke, S., Mattox, S., Bracy, P., Salmon, S., Jacobson, J., Crowley, J. & Tricot, G. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789-793.
4. Bartl, R., Frisch, B., Burkhardt, R., Fateh-Moghadam, A., Mahl, G., Gierster, P., Sund, M. & Kettner, G. (1982) Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. British Journal of Haematology, 51, 361-375.
5. Brereton, H.D., Anderson, T., Johnson, R.E. & Schein, P.S. (1975) Hyperphosphatemia and hypocalcemia in Burkitt's lymphoma: complications of chemotherapy. Archives of Internal Medicine, 135, 307-309.
6. Cohen, L.F., Balow, J.E., Magrath, I.T., Poplack, D.G. & Ziegler, J.L. (1980) Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. American Journal of Medicine, 68, 486-491.
7. Conger, J.D. (1990) Acute uric acid nephropathy. Medical Clinics of North America, 74, 859-871.
8. Dann, E.J., Gillis, S., Polliack, A., Okon, E., Rund, D. & Rachmilewitz, E.A. (1993) Tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. New England Journal of Medicine, 329, 1547-1548.
9. Desikan, R., Siegel, D., Fassas, A., Mehta, J., Singhal, S., Munshi, N., Anaissie, E., Ayers, D., Cromer, J., Spoon, D. & Barlogie, B. (1998) DCEP consolidation after tandem autotransplants (AT) in high risk multiple myeloma (MM): improved prognosis compared to matched historical controls. American Society of Hematology, 660a (abstract 2722).
10. Dimopoulos, M.A., Barlogie, B., Smith, T.L. & Alexanian, R. (1991) High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Annals of Internal Medicine, 115, 931-935.
11. Greipp, P.R., Leong, T., Bennett, J., Gaillard, J.P., Klein, B., Stewart, J.A., Oken, M.M., Kay, N.E., Van Ness, B. & Kyle, R.A. (1998) Plasmablastic morphology: an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood, 91, 2501-2507.
12. Greipp, P.R., Raymond, N.M., Kyle, R.A. & O'Fallon, W.M. (1985) Multiple myeloma: significance or plasmablastic subtype in morphological classification. Blood, 65, 305-310.
13. Hallek, M.P., Bergsagel, P.L. & Anderson, K.C. (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91, 3-21.
14. Kalemkerian, G.P., Darwish, B. & Varterasian, M.L. (1997) Tumor lysis syndrome in small cell carcinoma and other solid tumors. American Journal of Medicine, 103, 363-367.
15. Munshi, N.C., Desikan, K.R., Jagannath, S., Siegel, D., Bracy, D., Tricot, G. & Barlogie, B. (1996) Dexamethasone. cyclophosphamide, etoposide and Cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT). American Society of Hematology, 586a (abstract 2331).
16. O'Regan, S., Carson, S., Chesney, R.W. & Drummond, K.N. (1977) Electrolyte and acid-base disturbances in the management of leukemia. Blood, 49, 345-353.
17. Tricot, G., Barlogie, B., Jagganath, S., Bracy, D., Mattox, S., Vesole, D.H., Naucke, S. & Sawyer, J.R. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86, 4250-4256.
18. Tsokos, G.C., Balow, J.E., Spiegel, R.J. & Magrath, I.T. (1981) Renal and metabolic complications or undifferentiated and lymphoblastic lymphomas. Medicine, 60, 218-229.
19. Zusman, J., Brown, D.M. & Nesbit, M.E. (1973) Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. New England Journal of Medicine, 289, 1335-1340.